MAZE vs PG · $525.3M cap vs P/E 25, rev $84.28B
Maze Therapeutics, Inc. Common Stock (MAZE) versus Procter & Gamble Company (PG) — a side-by-side from cached financials, not a winner call.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
Procter & Gamble Company (PG) is a household & personal products company listed on US. It is led by Jon Moeller.
Latest reported MAZE revenue for 2025-06-30 was $0. Net income was -$66.5M. Revenue was down 100.0% from 2024-09-30 to 2025-06-30. MAZE currently screens at market cap $525.3M.
Latest reported PG revenue for 2025-06-30 was $84.28B. Net income was $15.97B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
MAZE currently screens at market cap $525.3M. PG currently screens at market cap $373.53B and trailing P/E 25.3.
Not investment advice. Open the MAZE and PG stock pages for the full models.
Not investment advice.